FINWIRES · TerminalLIVE
FINWIRES

Update: Dateline Resources Reports Pre-Tax NPV of $785 Million for California Project in Bankable Feasibility Study; Shares Down 16%

By

-- (Updates to add stock movement in the headline and the last paragraph)

Dateline Resources (ASX:DTR) said its bankable feasibility study (BFS) for its Colosseum gold and rare earth element project in California has returned a pre-tax net present value (NPV) of $785 million at a 5% discount rate and a pre-tax internal rate of return (IRR) of 49.5%, according to a Monday Australian bourse filing.

The company said undiscounted pre-tax free cash flow is $1.08 billion, rising to $1.36 billion at spot prices, with start-up capital of $249 million, including $16 million in capitalized mining costs, plus a $25 million contingency.

The project has a 10.4-year mine life producing 573,000 ounces of gold in total, with average annual gold production of 75,000 ounces over the first six years and peak gold sales of 102,000 ounces in year six, at an all-in sustaining cost (AISC) of $1,825 per ounce, the filing added.

The project has a low 3:1 strip ratio supporting lower operating costs, with 55,000 ounces of inferred mineral resources within the pit shell not included in the ore reserve, with the additional underground potential in the northeast of the North Pit open at depth and subject to ongoing drilling, the filing added.

The company's shares fell almost 16% in recent Monday trade.

Related Articles

Asia

Shenzhen LDROBOT Soars 103% in Hong Kong Trading Debut

Shenzhen LDROBOT's (HKG:1236) shares opened 102.9% above their initial public offering price in a stellar Hong Kong debut on Monday morning.The Chinese robotics company opened at HK$53.50 per share, well above the offer price of HK$26.36.

$HKG:1236
Asia

Concord Healthcare to Issue HK$68 Million Convertible Bonds to CSPC Pharma Unit

Concord Healthcare (HKG:2453) agreed to issue HK$68 million of convertible bonds to a unit of CSPC Pharmaceutical (HKG:1093), according to a Monday Hong Kong bourse filing.The oncology healthcare service provider said Dragon Merit will subscribe to the 2% convertible bonds due in April 2027.The bonds are convertible into as many as 40 million Hong Kong-listed shares at an initial conversion price of HK$1.70 per share, representing a premium of about 14.1% to the stock's last closing price.Net proceeds of about HK$63.1 million will mainly be used to repay loans and supplement working capital.Concord Healthcare said the investment is expected to deepen cooperation with CSPC Pharmaceutical in the oncology healthcare sector.

$HKG:1093$HKG:2453
Asia

Alterity Therapeutics Says Peer-Reviewed Study Validates its Approach to Multiple System Atrophy; Shares Fall 9%

Alterity Therapeutics (ASX:ATH) said findings of a study published in the NeuroImage journal support quantitative susceptibility mapping as an objective imaging biomarker to facilitate the earlier diagnosis of multiple system atrophy (MSA), according to a Monday filing with the Australian bourse.Alterity is advancing its ATH434 lead candidate into a phase three program for multiple system atrophy, a neurodegenerative disease that leads to the failure of the autonomic nervous system and impaired movement.The company said it used quantitative susceptibility mapping in a phase two trial in which ATH434 helped improve diagnostic accuracy and provided "objective evidence of target engagement."The peer-reviewed publication validates the company's approach and "reinforces the role of [quantitative susceptibility mapping] as a biomarker for iron-modulating therapies in MSA," Alterity CEO David Stamler said.The company's shares fell 9% in recent Monday trade.

$ASX:ATH